Prenosimo brojne vijesti MPN istraživačke fondacije. Godišnji sastanak Američkog društva za kliničku onkologiju (ASCO 2022) održan je u Chicagu. Europsko hematološko društvo (EHA) organiziralo je u Beču kongres EHA2022 u hibridnom obliku, a pristup virtualnoj platformi s brojnim temama (na primjer: selekcija pacijenata s mijelofibrozom za transplantaciju, razlike i sličnosti MDS-a i MPN-a, alogenična transplantacija matičnih stanica kod MDS-a i MPN-a…) bit će omogućen do 15. 8. 2023. godine. Pročitajte i ostale vijesti, kao i najavu radionice o mijeloproliferativnim neoplazmama u Teksasu u kolovozu ove godine, o kojoj detalje možete pročitati na poveznici u izvornom tekstu, kao i prijaviti se na nju.
Izvor: MPN RF

June 2022
MPN News from ASCO
Among the 85 livestream sessions and 2,500 poster presentations, this month’s American Society of Clinical Oncology 2022 Annual Meeting in Chicago featured a number of important findings regarding MPNs. Sharing MPN research updates with the full oncology community increases cross-discipline knowledge and fosters potentially broader collaborations that apply different perspectives to understanding and treating MPNs. A few key highlights follow. Watch for an in-depth report in the Summer Update, the MPNRF print newsletter. Subscribe Here
Rusfertide Shown to Reduce Phlebotomy 
“Most patients with PV are severely iron deficient, either due to their underlying disease or repeated phlebotomies,” according to Dr. Ronald Hoffman, MD, of Tisch Cancer Institute, Mount Sinai, who presented on two phase 2 studies of rusfertide treatment in phlebotomy-dependent PV (polycythemia vera) patients. Anemia is the major contributor to the hallmark fatigue reported by PV and other MPN patients.  
Rusfertide was shown to maintain target hematocrit levels < 45 percent, which measures the proportion of red cells in a person’s blood. Meeting this target reduced or eliminated the need for phlebotomy – a process that reduces overall blood volume – associated with varying hematocrit levels and contributing to anemia. In addition to the decreased risk of thrombosis, patients benefitted from a reduced symptom burden. Phase 3 of the rusfertide trial is currently recruiting.
Dr. Hoffman is one of a distinguished international group of academic advisors for MPNRF’s MPN Interferon Initiative
MOMENTUM Study Phase 3 Promising for Myelofibrosis  
“This study was designed specifically to highlight a select group of individuals for whom there is a significant unmet need,” according to Ruben Mesa, MD, Mays Cancer Center, UT Health San Antonio MD Anderson, who presented an update on the phase 3 randomized study of momelotinib versus danazol. Specifically, the trial is looking at symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. 
“It was superior to arguably our best alternative therapy for these patients (danazol),” he said. “Momelotinib was superior in terms of improvement in symptoms, and superior in terms of being transfusion free.” FDA approval of momelotinib for use in the treatment of myelofibrosis was filed 10 days after this ASCO presentation.
Dr. Mesa has been awarded multiple grants by MPNRF since 2003, including toward the creation of the practice changing MPN Symptom Assessment Form.  
Navtemadlin for MPN Progression to AML 
A poster session led by Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, presented findings of an open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) for patients with relapsed/refractory acute myeloid leukemia (AML) secondary to MPN.  
This patient group has limited treatment options, resulting in poor prognosis. Although conventional AML therapy can induce responses in a subset of patients, it does not prolong survival in AML secondary to MPN, according to the authors. They suggest that these studies provide biological and clinical support for evaluating navtemadlin in this patient population. This trial is ongoing and will enroll patients at 65 global sites. 
Dr. Rampal is medical advisor for the MPN Research Foundation.  
New Funding Opportunity: 2022 Thrive Initiative
The Thrive Initiative focuses on research funding gaps, including from pandemic impacts on the research community. The overall goal is to continue contributing to the scientific understanding of MPNs and how it can lead to better outcomes and eventual cures for MPN patients.  
• Advance existing MPN research projects the applicant is engaged in currently. 
• Foster growth and development of early career MPN researchers. 
• Attract established researchers in other fields to apply new ideas to MPN research. 
• Encourage collaborative translational projects with near-term clinical impact.  
The deadline for application submission is August 15. Learn More Here
EHA2022 MPN High Points from Vienna
Celebrating its 30th anniversary, the European Hematology Association’s EHA2022 Congress in Vienna brought together global research leaders, practitioners and other participants to share the latest advances in hematology. The hybrid event was June 9-12, with access to a virtual platform through August 15, 2023, where abstracts will be available. A few MPN highlights follow. 
How to select patients with myelofibrosis for transplantation and how to manage MF patients during  a transplant procedure.
Jean Jacques Kiladjian, Pr, MD, PhD, Hospital Saint-Louis and INSERM, Paris. 
Pegylated interferon-alfa found to control the differentiation of blood stem cells in MPNs, which could lead to new treatments to stop this process.   
Related abstract: 57 Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients.
Anna S Nam, MD, Weill Cornell Medicine, New York 
National quality of life survey across MPNs shows areas of patient/physician relationship needed improvement. 
Related abstract: Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark.
Tatiana Ianova, Multinational Center for Quality of Life Research, St. Petersburg 
Evaluation of the prognostic value of thrombophilia markers in patients with MPNs shows how some predictive biomarkers could be helpful to understand and inhibit MPN progression.  
Abstract not yet available. Tatyana Makarik, National Research Center for Hematology, Moscow 
Mutational studies elucidate differences and intersections of MPNs and myelodysplastic syndrome (MDS), which could lead to more accurate diagnosis and choice of treatment for these patients.  
Alejandro Pita, MD, Hepatobiliary Surgery, Transplantation, University Hospital of Salamanca, Spain 
Save the Date: Texas MPN Workshop 2022
Mays Cancer Center, home to UT Health San Antonio MD Anderson, hosts the 2022 Texas MPN Workshop, August 26-27. This third annual meeting on MPNs will be a hybrid event.
International MPN thought leaders and key investigators will gather to discuss new research and the many new therapy options in development for people living with essential thrombocythemia, polycythemia vera and myelofibrosis, including a deep dive into the role of current and new therapies. 
Within the two-day program, MPNRF is hosting a session titled, “MPN Disease from Pathogenesis to Progression.” See details and register here: Texas MPN Workshop
Clinical Trial Finder
The MPN Research Foundation clinical trial finder – powered by Trialjectory – creates a personalized list of current clinical trials that match an MPN patient’s diagnosis and medical history. Get Started Here: Clinical Trial Finder
Clinical Trial Highlights
Sponsor: Washington University School of Medicine 
Phase 2 trial for MF patients with severe thrombocytopenia who are able to travel to the trial site in St. Louis, MO. Fostamatinib is a tyrosine kinase inhibitor which was previously approved by the FDA for another indication. 
Navtemadlin/KRT-232 OR TL-895 
Company: Kartos Therapeutics 
Phase 2 trial for MF patients who have had no prior experience on a JAK2 inhibitor. Navtemadlin is an MDM2 inhibitor and TL-895 is a tyrosine kinase inhibitor. 
Our mission is supported by the generosity of our donors and sponsors.

Ostale informacije pročitajte u izvornom tekstu.
Izvor: MPN AN




MPN Advocates Network ADP project has kicked off!

We’re immensely excited for the first Advocate Development Programme (ADP) specifically developed for patient advocates for myeloproliferative neoplasms.

This training programme is designed to enable the participants to effectively advocate on behalf of their patient community on a political and societal level. Important topics are understanding clinical research and development, mechanisms of accessing diagnostics and drugs. Interaction with stakeholders such as clinicians and industry partners and the basics of evidence-based advocacy are an important part of the programme.

The monthly webinars are online sessions, with duration of 1.5 hours where each participant is able to learn from presentation by at least one expert speaker and a discussion amongst all participants to solidify and understand the learning objectives, and raise questions.

There are still new participants welcome, so if you would like to be part of the MPN AN ADP project, please contact Marija Stefkova:


EHA 2022 Patient Advocacy Hub

After 2 years, we were all looking forward to finally attending face-to-face conference. The European Hematology Association – EHA 2022 Congress took place in Vienna, Austria with about 11.000 participants from all over the globe and 4.000 more attended virtually.

MPN AN team was delighted to be a part of the EHA 2022 Congress in Vienna, Austria. We were stationed at the Patient Advocacy Hub where patient advocates were able to learn more about our organisation, our projects and team.



With great pleasure we would like to announce the dates for MPN Horizons 2022. November 18 – 20 are the dates you need to block on your calendar, and the venue will be further confirmed.

Keep track on our social media platforms and our website for more information!



Zagreb, HR

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
MB: 01136763
REG. BR.: 00000797
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
Web adresa:
IBAN: HR 36 2340 0091 1100 4711 4

Važni datumi

travanj 2024
































Health through Knowledge

Klasa optimist

Igor Delač- Samo zbog vas

(Ivan Zečić/Miroslav Zečić – Miroslav Zečić/Ivan Zečić) ℗ 2021 Croatia Records

Istaknuti sponzori HULL-a